Drug Profile
BNT 161
Alternative Names: BNT-161; PF 07252220; qIRV - BioNTech/Pfizer; Quadrivalent influenza modRNA vaccine - BioNTech/PfizerLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Influenza virus infections
Most Recent Events
- 27 Sep 2023 Pfizer completes a phase I trial in Influenza virus infections (In adults, In the elderly, Prevention, Combination therapy) in Argentina (IM) (NCT05788237)
- 09 Mar 2023 Phase-I clinical trials in Influenza virus infections (In adults, In the elderly, Prevention, Combination therapy) in Argentina (IM) (NCT05788237)
- 27 Jan 2023 Pfizer completes a phase I trials in Influenza virus infections (Prevention, In the elderly) in USA (IM) (NCT05052697)